Homeostatic Model Assessment for Insulin Resistance
HOMA IR
Description
"Homeostatic Model Assessment for Insulin Resistance" (HOMA-IR) test measures insulin resistance using fasting glucose and insulin values. It’s frequently used to evaluate metabolic syndrome, type 2 diabetes, or prediabetes risk. A high score suggests reduced insulin sensitivity, while a lower score indicates better glucose control. Doctors use results to guide early intervention strategies, including diet, exercise, or medications. Regular HOMA-IR testing helps detect changes early and supports long-term metabolic and cardiovascular health.
Category
Hormones
Procedure
Invasive
Sample Type
Blood – Serum
Units
Ratio
Procedure Category
Blood Draw
Test Group
Complete Blood Sugar Group, Pancreas Group
Test Group Description
Complete Blood Sugar Group: This expanded group includes a more comprehensive set of tests, offering a thorough evaluation of diverse facets of blood sugar levels for a more detailed understanding of metabolic health. Pancreas Group: Tests within this group focus on assessing the function and health of the pancreas, a vital organ involved in digestion and blood sugar regulation. These tests provide insights into pancreatic enzymes, hormone levels, and overall pancreatic function.
Optimal Range
For All Individuals:
Conventional Unit: 0.75–1.25 R
SI Unit: Not Applicable
Normal Range
For All Individuals:
Conventional Unit: 0.70–2.00 R
SI Unit: Not Applicable
Results That Differ From The Norm (Direct and Indirect Causes)
Increased levels may indicate:
Heart failure (inability of the heart to pump blood effectively)
Insulin resistance (Reduced sensitivity to insulin)
Metabolic syndrome (cluster of conditions including high blood pressure, high blood sugar, excess body fat around the waist, and abnormal cholesterol levels)
Obesity
Polycystic ovary syndrome (Hormonal diso...
Key Reasons For Testing
Insulin Sensitivity: Assesses tissue response to insulin, providing insights into glucose regulation.
Insulin Resistance: Identifies resistance and related disorders using HOMA-IR values.
Treatment Monitoring: Tracks therapy responses, supporting adjustments for improved control.
Risk Prediction: Evaluates risks for diabetes and cardiovascular disease to guide prevention.
Health Status Conditions It May Be Used To Assess
Currently, this test is not directly associated with any conditions listed on the Health Status page. However, it may be included as part of a broader set of tests linked to specific health conditions.
Some Prominent Medical Labs That May Offer This Test
Please note that this particular test has not been associated with any of the listed prominent medical labs. We recommend enquiring with your private physician or nearest hospital to determine where this specific test can be performed.
References
Important Note
Any medical procedure yielding results outside the norm may be directly or indirectly linked to the conditions outlined on this page. Various factors, including genetics, medication and supplement usage, recent illnesses, pregnancy, pre-test eating, smoking, and stress, can impact the test's outcome. Additionally, factors like false positives, false negatives, inaccurate analyses, and others can influence results.
Reference ranges, which help healthcare professionals interpret medical tests, may vary depending on age, gender, and other factors. They may also differ between laboratories due to variations in instruments and methods used. Optimal ranges are designed for preventive purposes, aiming to identify trends and potential risks early, while normal ranges reflect conventional laboratory values indicating no current disease or pathology. Your healthcare practitioner may have specific reasons for testing that deviate from the usual or may interpret results differently based on individual circumstances. Proper interpretation typically involves considering clinical findings and other diagnostic tests. Hence, it is crucial to provide your healthcare professionals with a comprehensive medical history, consult with them for result interpretation, and follow their guidance for potential re-testing or additional diagnostics.
Disclaimer
This content is provided solely for informative and educational purposes. It is not intended as a substitute for medical advice or treatment from a personal physician. Regarding the interpretation of their medical test results and/or specific health questions, it is recommended that all readers and viewers consult their physicians or other qualified health professionals. The publisher is not responsible for any adverse health effects that may result from reading or following the information in this educational content. Before beginning any nutrition, supplement, or lifestyle program, all viewers, especially those taking prescription or over-the-counter medications, should consult their physician or health care practitioner.
Please note that while prominent lab names are included in this content, we cannot guarantee that these labs offer all the tests mentioned. For confirmation, individuals should contact the labs directly or consult their medical practitioners. The information provided reflects general knowledge at the time of publication and may not include recent updates or emerging research. Readers should verify details with qualified professionals to ensure the most up-to-date and accurate guidance.
[1] Felton JL, Cuthbertson D, Warnock M, et al. HOMA2-B enhances assessment of type 1 diabetes risk among TrialNet Pathway to Prevention participants. Diabetologia. 2022;65(1):88-100.
[2] Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412-419.
[3] Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care. 2004;27(6):1487-1495.
[4] Bonora E, Targher G, Alberiche M, et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care. 2000;23(1):57-63.
[5] Geloneze B, Vasques AC, Stabe CF, et al. HOMA1-IR and HOMA2-IR indexes in identifying insulin resistance and metabolic syndrome. Diabetes Care. 2009;32(5):873-875.
[6] Yokoyama H, Emoto M, Araki T, et al. Effectiveness of HOMA-IR and the metabolic syndrome criteria in predicting type 2 diabetes in a Japanese population. Diabetes Res Clin Pract. 2007;77(2):249-256.
[7] Keskin M, Kurtoglu S, Kendirci M, et al. Homeostasis model assessment is more reliable than the fasting glucose/insulin ratio and quantitative insulin sensitivity check index for assessing insulin resistance among obese children and adolescents. Pediatrics. 2005;115(4):e500-e503.
[8] Radziuk J. Insulin sensitivity and its measurement: structural commonalities among the methods. J Clin Endocrinol Metab. 2000;85(12):4426-4433.
[9] Simental-Mendía LE, Rodríguez-Morán M, Guerrero-Romero F. The product of fasting glucose and triglycerides as surrogate for identifying insulin resistance: a comparison with the HOMA-IR index. Diabetes Res Clin Pract.2008;82(2):278-285.
[10] Song Y, Manson JE, Tinker L, et al. Insulin sensitivity and insulin secretion determined by the Homeostasis Model Assessment (HOMA) and risk of diabetes in a multiethnic cohort of women. Diabetes Care. 2007;30(7):1747-1752.
[11] Meigs JB, Wilson PW, Nathan DM, et al. Prevalence and characteristics of the metabolic syndrome in the San Antonio Heart and Framingham Offspring Studies. Diabetes. 2003;52(8):2160-2167.
[12] Hu FB, Li TY, Colditz GA, et al. Television watching and other sedentary behaviors in relation to risk of obesity and type 2 diabetes mellitus in women. JAMA. 2003;289(14):1785-1791.
[13] Antuna-Puente B, Disse E, Rabasa-Lhoret R, et al. How can we measure insulin sensitivity/resistance? Diabetes Metab. 2011;37(3):179-188.
[14] Faerch K, Borch-Johnsen K, Vaag A, et al. Sex differences in glucose levels: a consequence of physiology or methodological convenience? The Inter99 study. Diabetologia. 2010;53(5):858-865.